Biotech - Spark Newswire

1 minute read

Noting Strong Progress On Marinus Pharma’s Lead Drug Ganaxolone, Analyst Initiates With 300% Upside

Today, 4:18 PM

RBC Capital Markets initiated coverage on Marinus Pharmaceuticals Inc (NASDAQ:MRNS) with an Outperform rating, Speculative Risk, and a price target of…

MRNS

1 minute read

Jazz Pharma, Zymeworks Highlight 84% Overall Survival At 18 Months From Zanidatamab In Esophageal Cancer

By Vandana Singh

Today, 4:18 PM

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Zymeworks Inc (NASDAQ:ZYME) announced tolerability and efficacy results, including the first overall survival (OS) data, from…

JAZZ

1 minute read

Horizon Therapeutics Touts Positive Data From Mid-Stage Study For Immune System Disorder

By Vandana Singh

Today, 4:18 PM

Horizon Therapeutics plc’s (NASDAQ:HZNP) Phase 2 trial evaluating dazodalibep for Sjögren’s syndrome met its primary endpoint in the second patient…

HZNP

1 minute read

Johnson & Johnson’s HIV Vaccine Regimen Does Not Prevent Infection, Phase 3 Study Shows

By Vandana Singh

Today, 4:18 PM

The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) announced the results of an independent, scheduled data review of the Phase 3 Mosaico study of the investigational HIV vaccine regimen.

JNJ

2 minute read

US Health Agencies Investigate Preliminary COVID-19 Vaccine Safety Signal In Older People

By Vandana Singh

Today, 4:18 PM

The U.S.

BNTX

2 minute read

Amazon’s Jeff Bezos Paid $3B With The Hope He’ll Live Longer — Here’s The Problem

By Melanie Schaffer

Today, 4:18 PM

Rejuvenation is no longer just for the human face but possibly the human race, according to a small biotech company that claims it has developed technology that extends the lifespan of mice by 7%.

AMZN

2 minute read

Xbox Goes Green: Revolutionary Update Helps Users Significantly Reduce Carbon Footprint

By Franca Quarneti

Today, 4:18 PM

Microsoft (NASDAQ: MSFT)’s Xbox is getting a new update that aims to help console owners reduce their carbon emissions.

MSFT

1 minute read

Capricor Highlights Preclinical Data From Its Closed COVID-19 Vaccine Study

By Vandana Singh

Today, 4:18 PM

Capricor Therapeutics (NASDAQ:CAPR) announced the publication of a preclinical study online in bioRxiv and explored Capricor’s proprietary StealthX exosome platform’s therapeutic potential, generating…

CAPR

1 minute read

Reported Late Wednesday, Oramed Pharmaceuticals Announces Top-line Results From Phase 3 Trial Of ORMD-0801 For The Treatment Of Type 2 Diabetes; The ORA-D-013-1 Trial Did Not Meet Its Primary Endpoint

By Benzinga Newsdesk

Today, 4:18 PM

Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today top-line results from its Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial (ORA-D-013-1) comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes (T2D) at 26 weeks.

ORMP

1 minute read

Macro Factors Take a Toll on Cutera Earnings, Analyst Slashes Price Target by 61%

By Vandana Singh

Today, 4:18 PM

Earlier this week, Cutera Inc (NASDAQ:CUTR) reported interim FY22 sales of $252 million to $253 million for full-year 2022, growing 15% to…

CUTR